ABT-737 is highly effective against molecular subgroups of multiple myeloma

Blood

Volumn 118, Issue 14, 2011, Pages 3901-3910

  Bodet, Linda ^a,b   Gomez Bougie, Patricia ^a,b,c   Touzeau, Cyrille ^a,c   Dousset, Christelle ^a,b,c   Descamps, Géraldine ^a,b   Maïga, Sophie ^a,b   Avet Loiseau, Hervé ^c   Bataille, Régis ^a,b   Moreau, Philippe ^c   Le Gouill, Steven ^a,c   Pellat Deceunynck, Catherine ^a,b   Amiot, Martine ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b Equipe 10 Labellisée Ligue Nationale Contre le Cancer 2008   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; HETERODIMER; NAVITOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PUMA PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL SELECTION; DRUG EFFICACY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 80053653073     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-317438     Document Type: Article

References (34)

1. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutical potential. Curr Opin Immunol. 2007;19(5):488-496. (Pubitemid 47487452)
2. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292(5517):727-730. (Pubitemid 32385543)
3. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(1):296-303. (Pubitemid 40967205)
4. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221.
5. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028. (Pubitemid 44395016)
6. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100(1):194-199. (Pubitemid 35177447)
7. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99(6):1885-1893. (Pubitemid 34525465)
8. Wuillème-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19(7):1248-1252. (Pubitemid 40946011)
9. Bodet L, Ménoret E, Descamps G, et al. BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. Br J Cancer. 2010;103(12):1808-1814.
10. Moreaux J, Klein B, Bataille R, et al. Human myeloma cell lines (HMCLs) reflect the molecular diversity of primary myeloma cells. Haematologica. 2011;96(4):574-582.
11. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature. 2005;435(7042):677- 681. (Pubitemid 40825512)
12. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112-121. (Pubitemid 46048458)
13. Zhang XG, Gaillard JP, Robillard N, et al. Reproductible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83(12):3654-3663. (Pubitemid 24175556)
14. Rème T, Hose D, De Vos J, et al. A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics. 2008;9:16-28.
15. Le Carrour T, Assou S, Tondeur S, et al. Amazonia!: an online resource to Google and visualize public human whole genome expression data. Open Bioinformatics J. 2010;4:5-10.
16. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response toABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12(2):171-185. (Pubitemid 47199122)
17. Van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389-399. (Pubitemid 44711953)
18. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007;67(3):1176-1183.
19. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351-365. (Pubitemid 43668734)
20. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008;27(suppl 1):S149-S157.
21. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393-403. (Pubitemid 40193310)
22. Gallenne T, Gautier F, Oliver L, et al. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol. 2009;185(2):279-290.
23. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375-388. (Pubitemid 44693472)
24. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008;111(4):2300-2309. (Pubitemid 351451437)
25. Vogler M, Dinsdale D, Sun XM, et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ. 2008;15(5):820-830. (Pubitemid 351524424)
26. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26(16):2374- 2380. (Pubitemid 46572819)
27. Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia. 2007;21(7):1549-1560. (Pubitemid 46965297)
28. Trudel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res. 2007;13(2):621-629. (Pubitemid 46225369)
29. Olejniczak ET, Van Sant C, Anderson MG, et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res. 2007;5(4):331-339. (Pubitemid 46706995)
30. Nair B, Van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115(21):4168-4173.
31. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
32. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29(7):909-916.
33. Roberts AW, Brown J, Seymour JF, et al. An ongoing phase & study of ABT-263; pharmacokinetics, safety and anti-tumor activity in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood. 2008;112: Abstract 3177.
34. Wilson WH, Czuczman MS, LaCasce AS, et al. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies [abstract]. J Clin Oncol. 2008;26: Abstract 8511.